{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Cell+Carcinoma&page=7", "query": { "condition": "Renal Cell Carcinoma", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 1512, "total_pages": 152, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Cell+Carcinoma&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Cell+Carcinoma&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T22:22:14.083Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01480154", "title": "Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Stage III Cutaneous Melanoma AJCC v7", "Stage III Prostate Cancer AJCC v7", "Stage III Renal Cell Cancer AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Prostate Cancer AJCC v7", "Stage IV Renal Cell Cancer AJCC v7" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2011-11-23", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-10T22:22:14.083Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01480154" }, { "nct_id": "NCT00529802", "title": "Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "RAD001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2007-09", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2018-04-25", "last_synced_at": "2026-10-10T22:22:14.083Z", "location_count": 5, "location_summary": "Chicago, Illinois • Peoria, Illinois • Boston, Massachusetts + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00529802" }, { "nct_id": "NCT01975831", "title": "A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Ovarian Cancer", "Colorectal Cancer", "Cervical Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ludwig Institute for Cancer Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2013-12-19", "completion_date": "2021-07-02", "has_results": true, "last_update_posted_date": "2022-10-12", "last_synced_at": "2026-10-10T22:22:14.083Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Buffalo, New York + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01975831" }, { "nct_id": "NCT00005831", "title": "Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Bladder Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Squamous Cell Carcinoma of the Bladder", "Stage IV Bladder Cancer", "Transitional Cell Carcinoma of the Bladder" ], "interventions": [ { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2000-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-14", "last_synced_at": "2026-10-10T22:22:14.083Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005831" }, { "nct_id": "NCT03758781", "title": "IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Recurrent Cancer", "Solid Tumor", "Renal Cell Carcinoma", "Urothelial Carcinoma", "NSCLC", "Squamous Cell Carcinoma", "Non-Small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "IRX 2", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2019-02-13", "completion_date": "2021-08-11", "has_results": false, "last_update_posted_date": "2023-04-14", "last_synced_at": "2026-10-10T22:22:14.083Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03758781" }, { "nct_id": "NCT01183663", "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2010-08", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-10-10T22:22:14.083Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183663" }, { "nct_id": "NCT00655655", "title": "Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrinoma", "Glucagonoma", "Insulinoma", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic Pheochromocytoma", "Pancreatic Polypeptide Tumor", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Recurrent Melanoma", "Recurrent Neuroendocrine Carcinoma of the Skin", "Recurrent Non-small Cell Lung Cancer", "Recurrent Pheochromocytoma", "Recurrent Renal Cell Cancer", "Somatostatinoma", "Stage III Neuroendocrine Carcinoma of the Skin", "Stage IV Melanoma", "Stage IV Non-small Cell Lung Cancer", "Stage IV Renal Cell Cancer", "Thyroid Gland Medullary Carcinoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "vatalanib", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "dynamic contrast-enhanced magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "ultrasound imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2004-12", "completion_date": "2018-01-11", "has_results": false, "last_update_posted_date": "2024-08-21", "last_synced_at": "2026-10-10T22:22:14.083Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00655655" }, { "nct_id": "NCT01391143", "title": "Safety Study of MGA271 in Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer", "Melanoma", "Renal Cell Carcinoma", "Triple-negative Breast Cancer", "Head and Neck Cancer", "Bladder Cancer", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "MGA271", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 179, "start_date": "2011-07", "completion_date": "2019-04-18", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-10-10T22:22:14.083Z", "location_count": 12, "location_summary": "Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01391143" }, { "nct_id": "NCT06582017", "title": "Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Pancreas Cancer", "Urothelial Carcinoma", "Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Gastrointestinal Cancer", "Lung Cancer", "Prostate Cancer", "Breast Cancer" ], "interventions": [ { "name": "QXL138AM Injection every 2 weeks by IV Infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nammi Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-08-28", "completion_date": "2028-05-30", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-10T22:22:14.083Z", "location_count": 10, "location_summary": "Los Angeles, California • Newport, California • Denver, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06582017" }, { "nct_id": "NCT00088374", "title": "17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hippel-Lindau Disease", "Kidney Cancer" ], "interventions": [ { "name": "17 allylamino-17-demethoxygeldanamycin", "type": "DRUG" }, { "name": "18 FDG (Fludeoxyglucose 18F)", "type": "DRUG" }, { "name": "[15-O] H2O", "type": "DRUG" }, { "name": "EPL diluent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2004-07", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2012-07-27", "last_synced_at": "2026-10-10T22:22:14.083Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00088374" } ] }